Category: <span>tremelimumab</span>

Category: tremelimumab

Baylor St. Luke’s Medical Center, clinical trials, Dr. David Sugarbaker, Immunotherapy, mesothelioma cancer, Mesothelioma News, Mesothelioma Treatment Center, tremelimumab

New Mesothelioma Immunotherapy Clinical Trial at Baylor University

 

A new clinical trial at Baylor University’s Mesothelioma Treatment Center is looking at the effectiveness of using immunotherapy before surgery.

anti-CTLA-4, AstraZeneca, FDA, ipilimumab, Malignant mesothelioma, mesothelioma, Mesothelioma News, Orphan Drug, Orphan Drug Act of January 1983, Robert Iannone, tremelimumab

FDA Grants AstraZeneca’s Tremelimumab Orphan Drug Status for Mesothelioma

 

AstraZeneca’s tremelimumab (anti-CTLA-4 monoclonal antibody) has received Orphan Drug status from the FDA for treating malignant mesothelioma.